Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Q4 2025 value amounting to 0.26%.

  • Arrowhead Pharmaceuticals' Return on Capital Employed rose 9000.0% to 0.26% in Q4 2025 from the same period last year, while for Dec 2025 it was 0.26%, marking a year-over-year increase of 9000.0%. This contributed to the annual value of 0.09% for FY2025, which is 8000.0% up from last year.
  • Per Arrowhead Pharmaceuticals' latest filing, its Return on Capital Employed stood at 0.26% for Q4 2025, which was up 9000.0% from 0.08% recorded in Q3 2025.
  • Arrowhead Pharmaceuticals' Return on Capital Employed's 5-year high stood at 0.26% during Q4 2025, with a 5-year trough of 0.67% in Q2 2024.
  • Its 5-year average for Return on Capital Employed is 0.29%, with a median of 0.26% in 2021.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first tumbled by -4700bps in 2024, then surged by 9000bps in 2025.
  • Arrowhead Pharmaceuticals' Return on Capital Employed (Quarter) stood at 0.35% in 2021, then skyrocketed by 33bps to 0.23% in 2022, then crashed by -102bps to 0.47% in 2023, then crashed by -34bps to 0.64% in 2024, then surged by 141bps to 0.26% in 2025.
  • Its Return on Capital Employed was 0.26% in Q4 2025, compared to 0.08% in Q3 2025 and 0.08% in Q2 2025.